These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22119746)

  • 1. Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial.
    Kusumi I; Honda M; Uemura K; Sugawara Y; Kohsaka M; Tochigi A; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):313-7. PubMed ID: 22119746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
    Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
    Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.
    Bitter I; Treuer T; Dilbaz N; Oyffe I; Ciorabai EM; Gonzalez SL; Ruschel S; Salburg J; Dyachkova Y
    World J Biol Psychiatry; 2010 Oct; 11(7):894-903. PubMed ID: 20653494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.
    Kozumplik O; Uzun S; Jakovljević M
    Psychiatr Danub; 2009 Mar; 21(1):72-4. PubMed ID: 19270625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.
    Chawla B; Luxton-Andrew H
    Hum Psychopharmacol; 2008 Apr; 23(3):211-6. PubMed ID: 18219624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression.
    Bobo WV; Epstein RA; Shelton RC
    Ann Clin Psychiatry; 2011 Aug; 23(3):193-201. PubMed ID: 21808751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.
    Crocq MA; Guillon MS; Bailey PE; Provost D
    Eur Psychiatry; 2007 Oct; 22(7):453-4. PubMed ID: 17761403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.
    Karagianis J; Grossman L; Landry J; Reed VA; de Haan L; Maguire GA; Hoffmann VP; Milev R
    Schizophr Res; 2009 Aug; 113(1):41-8. PubMed ID: 19535229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.
    Vidarsdottir S; Vlug P; Roelfsema F; Frölich M; Pijl H
    J Clin Psychiatry; 2010 Sep; 71(9):1205-11. PubMed ID: 20441717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.
    Arranz B; San L; Dueñas RM; Centeno M; Ramirez N; Salavert J; Del Moral E
    Hum Psychopharmacol; 2007 Jan; 22(1):11-5. PubMed ID: 17191265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
    Kinon BJ; Lipkovich I; Edwards SB; Adams DH; Ascher-Svanum H; Siris SG
    J Clin Psychopharmacol; 2006 Apr; 26(2):157-62. PubMed ID: 16633144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
    Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
    BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.